Acute severe ulcerative colitis: using JAK-STAT inhibitors for improved clinical outcomes

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Acute Severe Ulcerative Colitis (ASUC) is a life-threatening condition requiring immediate diagnosis and management.
• Failure to treat ASUC can lead to severe complications like toxic dilation, hemorrhage, or sepsis.
• Current treatment involves IV corticosteroids, followed by oral agents, calcineurin inhibitors, or TNF inhibitors like Infliximab (IFX).

Purpose of the Study:

• To discuss optimizing Infliximab (IFX) dosing for enhanced efficacy in ASUC.
• To explore the safety and efficacy of Janus Kinase (JAK-STAT) inhibitors as salvage therapy for IFX failure.
• To propose a novel treatment algorithm to improve clinical outcomes in medically managed ASUC patients.

Main Methods:

• Review of current treatment algorithms for ASUC.
• Analysis of data on Infliximab (IFX) efficacy and limitations.
• Exploration of recent studies on JAK-STAT inhibitors (Tofacitinib, Upadacitinib) for salvage therapy.

Main Results:

• Infliximab (IFX) shows short-term efficacy but faces challenges in long-term remission maintenance.
• JAK-STAT inhibitors demonstrate potential as salvage therapy for IFX failure.
• Optimizing IFX dosing and incorporating JAK-STAT inhibitors may improve treatment outcomes.

Conclusions:

• Further research is needed to optimize IFX dosing strategies.
• JAK-STAT inhibitors represent a promising salvage option for ASUC patients.
• A novel treatment algorithm integrating optimized IFX and JAK-STAT inhibitors could enhance clinical outcomes in ASUC.